FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 06:53:07 2024-05-23 am EDT | ||
| 8.25 EUR / 8.26 EUR | -4.01% |
|
| Current month | -6.83% | ||
| 1 month | -10.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 8.27 | -3.84% |
| 24-05-22 | 8.6 | -2.27% |
| 24-05-21 | 8.8 | +0.69% |
| 24-05-20 | 8.74 | -2.78% |
| 24-05-17 | 8.99 | +2.74% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 04:24 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF2 |
| ISIN | DE000MG1SF25 |
| Date issued | 2024-04-05 |
| Strike | 1,391 kr |
| Maturity | Unlimited |
| Parity | 7.29 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.59 € |
|---|---|
| Lowest since issue | 8.27 € |
| Spread | 0.01 € |
| Spread % | 0.12% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- Certificat
